Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 1;9(2):124.
doi: 10.3390/antiox9020124.

Dicarbonyl Stress and S-Glutathionylation in Cerebrovascular Diseases: A Focus on Cerebral Cavernous Malformations

Affiliations
Review

Dicarbonyl Stress and S-Glutathionylation in Cerebrovascular Diseases: A Focus on Cerebral Cavernous Malformations

Cinzia Antognelli et al. Antioxidants (Basel). .

Abstract

Dicarbonyl stress is a dysfunctional state consisting in the abnormal accumulation of reactive α-oxaldehydes leading to increased protein modification. In cells, post-translational changes can also occur through S-glutathionylation, a highly conserved oxidative post-translational modification consisting of the formation of a mixed disulfide between glutathione and a protein cysteine residue. This review recapitulates the main findings supporting a role for dicarbonyl stress and S-glutathionylation in the pathogenesis of cerebrovascular diseases, with specific emphasis on cerebral cavernous malformations (CCM), a vascular disease of proven genetic origin that may give rise to various clinical signs and symptoms at any age, including recurrent headaches, seizures, focal neurological deficits, and intracerebral hemorrhage. A possible interplay between dicarbonyl stress and S-glutathionylation in CCM is also discussed.

Keywords: S-glutathionylation; advanced glycation end products; cerebral cavernous malformations; cerebrovascular disease; dicarbonyl stress; glutathione; glyoxalase 1; methylglyoxal; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Schematic model of the glyoxalase system. The glyoxalase system consists of two glyoxalase enzymes, Glyoxalase 1 (Glo1) and Glyoxalase 2 (Glo2), and a catalytic amount of glutathione (GSH). Glo1 converts the hemithioacetal spontaneously formed between methylglyoxal (MG) and GSH to S-D-lactoylglutathione (SLG), whereas Glo2 catalyses the hydrolysis of SLG to D-lactate (D-LAC), regenerating GSH.
Figure 2
Figure 2
Potential interplay between methylglyoxal (MG)-mediated glycation and S-glutathionylation pathways induced by KRIT1 (Krev interaction trapped 1) loss-of-function. The impairement of intracellular redox homeostasis caused by KRIT1 loss-of-function leads to a reactive oxygen species (ROS)-dependent sustained activation of the JNK-Nrf2 (c-Jun N-terminal kinase -nuclear factor erythroid 2-related factor) pathway and upregulation of downstram targets, including Glyoxalase 1 (Glo1). In turn, Glo1 upregulation results in decreased intracellular levels of cytoprotective MG adducts, including argpyrimidine (AP)-modified heat-shock proteins (HSP) 27 and 70, leading to an increased cell susceptibility to oxidative damage and mitochondria-dependent apoptosis. Concomitantly, KRIT1 loss-of-function affects the glutathione (GSH) redox system, causing a significant decrease in the GSH:GSSG redox ratio and an increase in the S-glutathionylation of important structural and regulatory proteins, including metabolic enzymes; cytoskeletal proteins; and chaperonines, such as the HSP60. A potential interplay between the MG-mediated glycation and S-glutathionylation pathways may also occur, including the modulation of the GSH:GSSG redox ratio by MG and the contribution of S-glutathionylation to ROS production and Nrf2 activation (hatched red lines), leading to a synergistic contribution to the chronic adaptive redox homeostasis and enhanced cell susceptibility to oxidative stress associated with KRIT1 loss-of-function mutations. Eventually, these synergistic pathological effects might therefore culminate in cerebral cavernous malformation (CCM) disease onset and severity. See text for details.

References

    1. Feigin V.L., Forouzanfar M.H., Krishnamurthi R., Mensah G.A., Connor M., Bennett D.A., Moran A.E., Sacco R.L., Anderson L., Truelsen T., et al. Global and regional burden of stroke during 1990-2010: Findings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245–254. doi: 10.1016/S0140-6736(13)61953-4. - DOI - PMC - PubMed
    1. Trapani E., Retta S.F. Cerebral cavernous malformation (CCM) disease: From monogenic forms to genetic susceptibility factors. J. Neurosurg. Sci. 2015;59:201–209. - PubMed
    1. Choquet H., Trapani E., Goitre L., Trabalzini L., Akers A., Fontanella M., Hart B.L., Morrison L.A., Pawlikowska L., Kim H., et al. Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1. Free Radic. Biol. Med. 2016;92:100–109. doi: 10.1016/j.freeradbiomed.2016.01.008. - DOI - PMC - PubMed
    1. Della-Morte D., Pacifici F., Rundek T. Genetic susceptibility to cerebrovascular disease. Curr. Opin. Lipidol. 2016;27:187–195. doi: 10.1097/MOL.0000000000000275. - DOI - PMC - PubMed
    1. Chrissobolis S., Miller A.A., Drummond G.R., Kemp-Harper B.K., Sobey C.G. Oxidative stress and endothelial dysfunction in cerebrovascular disease. Front. Biosci. 2011;16:1733–1745. doi: 10.2741/3816. - DOI - PubMed